How to Get Dayvigo (Lemborexant) in Indiana

What Is Dayvigo and How Does It Work?

Dayvigo is the brand name for lemborexant, a dual orexin receptor antagonist (DORA) that blocks OX1R and OX2R receptors to reduce wake-promoting signaling at bedtime. The FDA approved lemborexant in December 2019 for adults with insomnia characterized by difficulties with sleep onset, sleep maintenance, or both. Unlike benzodiazepines and Z-drugs, it does not broadly suppress the central nervous system but instead selectively quiets the orexin wake-drive [1].

The SUNRISE-1 trial, published in JAMA Network Open (N=1,006 adults with insomnia disorder), compared lemborexant 5 mg and 10 mg against zolpidem tartrate extended-release 6.25 mg over 30 nights. Lemborexant 10 mg reduced subjective sleep onset latency by a mean of 17.4 minutes from baseline versus 10.9 minutes for zolpidem ER, and the difference reached statistical significance (P<0.05) [2]. Lemborexant 5 mg also outperformed placebo on sleep onset and wake after sleep onset (WASO) endpoints.

SUNRISE-2, a 12-month randomized, double-blind trial, demonstrated sustained efficacy. Lemborexant 5 mg and 10 mg both produced statistically significant improvements in subjective total sleep time compared with placebo through week 52, with no evidence of rebound insomnia on discontinuation [3]. The FDA label notes next-morning driving impairment is dose-dependent, which is why 5 mg is the recommended starting dose for most adults [1].

Eisai's mechanism differs from earlier sleep drugs in a clinically meaningful way. Zolpidem targets GABA-A receptors across multiple brain regions, whereas lemborexant acts only on the two orexin receptor subtypes. That selectivity translates to a lower risk of motor impairment, respiratory depression, and abuse, though Schedule IV scheduling still applies because of the sedative nature of the drug [4].

Indiana Prescribing Law: Who Can Write the Prescription?

Any Indiana-licensed physician (MD or DO), nurse practitioner (NP) with full prescriptive authority, or physician assistant (PA) with a valid Indiana controlled-substance registration may prescribe lemborexant. Indiana grants full practice authority to NPs under IC 25-23-1-19.4, meaning NP-staffed telehealth clinics can issue Schedule IV prescriptions without a physician co-signature.

PAs in Indiana practice under a supervision agreement, but that agreement does not prevent them from prescribing Schedule IV substances if the supervising physician's DEA registration covers the drug class. Dentists and optometrists are not authorized to prescribe insomnia medications under their Indiana scope of practice.

All prescribers must hold an active DEA registration with Schedule IV authority. Indiana also requires prescribers to query the Indiana Prescription Drug Monitoring Program (INSPECT) database before issuing or renewing a Schedule IV prescription [5]. Telehealth providers licensed in Indiana carry the same obligation. Failure to query INSPECT is a disciplinary violation under Indiana Administrative Code 844 IAC 5-2.

Telehealth Access: Getting Dayvigo Online in Indiana

Indiana telehealth prescribing of Schedule IV controlled substances is permitted under Indiana Code 25-1-9.5, which aligns with the federal Ryan Haight Act framework. A valid patient-provider relationship must be established before a controlled-substance prescription is issued. For most telehealth platforms, that means a synchronous audio-video visit rather than an asynchronous questionnaire alone.

The DEA's temporary COVID-era telemedicine flexibilities, which allowed Schedule IV prescriptions after an audio-only visit, expired in 2023. A registered telehealth provider in Indiana must conduct a real-time video examination, review prior medical records or a sleep history questionnaire, query INSPECT, and document a diagnosis of insomnia disorder (ICD-10 G47.00) before transmitting the prescription electronically to a pharmacy [6].

Practical steps for an Indiana patient:

1. Book a video visit with an Indiana-licensed telehealth provider (or an out-of-state provider with an Indiana telehealth registration).
2. Complete the pre-visit intake covering sleep latency, WASO, daytime impairment, and current medications.
3. Attend the video visit. The clinician will rule out contraindications such as narcolepsy, severe hepatic impairment, and concurrent CNS depressants.
4. If appropriate, the provider transmits an e-prescription for lemborexant 5 mg #30 with instructions to take one tablet within 30 minutes of bedtime.
5. Choose a mail-order or local Indiana pharmacy to fill the prescription.

Most established telehealth platforms complete steps one through four on the same day. Pharmacy dispensing adds one to five business days depending on in-stock status and shipping method.

What Labs Are Needed Before Starting Dayvigo in Indiana?

No mandatory laboratory testing is required by the FDA label or by Indiana prescribing regulations before initiating lemborexant [1]. The drug is not metabolized by a pathway that requires baseline organ-function panels in otherwise healthy adults. CYP3A is the primary metabolic route, so the clinician will ask about concurrent CYP3A inhibitors or inducers rather than ordering a metabolic panel.

Clinicians typically review the following before prescribing:

• A validated insomnia severity instrument such as the Insomnia Severity Index (ISI) or the Pittsburgh Sleep Quality Index (PSQI). An ISI score of 15 or above indicates moderate-to-severe clinical insomnia [7].
• Current medication list to check for strong CYP3A inhibitors (e.g., clarithromycin, itraconazole), which can raise lemborexant plasma levels significantly and require dose reduction to 5 mg maximum [1].
• A brief history to screen for sleep apnea, since lemborexant is not recommended in patients with severe obstructive sleep apnea because of the theoretical risk of respiratory compromise [1].
• Pregnancy status. The FDA classifies the drug as Pregnancy Category: data insufficient; animal studies showed embryo-fetal toxicity at high doses [1].

A polysomnogram is not required for diagnosis or prescription. Clinical history consistent with DSM-5 criteria for insomnia disorder suffices, which is why telehealth intake is well-suited to this indication [8].

Prior Authorization in Indiana: What Documentation Is Required?

Most commercial Indiana health plans place Dayvigo on a non-preferred tier requiring prior authorization (PA). Indiana Medicaid (Hoosier Health) does not cover lemborexant for insomnia; coverage is limited to a diabetes-related indication. Patients on Indiana Medicaid must pay out of pocket or use a manufacturer coupon unless an appeal succeeds.

For commercial PA, documentation commonly required includes:

• Documented diagnosis of insomnia disorder with onset and duration.
• Evidence of a trial-and-failure of at least one preferred formulary agent, typically a generic Z-drug such as zolpidem tartrate or eszopiclone, for a minimum of 30 days.
• Clinical rationale for why the preferred agent was inadequate or contraindicated. Common reasons include residual sedation with zolpidem, a history of parasomnias on Z-drugs, or a clinical need to minimize respiratory depression risk.
• Prescriber NPI and DEA number.
• Expected duration of therapy.

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for Chronic Insomnia Disorder in Adults states: "We suggest that clinicians use lemborexant as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults" at a conditional recommendation level based on moderate-quality evidence [9]. Quoting this guideline in a PA letter strengthens medical-necessity arguments.

Eisai provides a Dayvigo Patient Savings Program for commercially insured patients who qualify; eligible patients may pay as little as $15 per 30-day supply. The savings program does not apply to federal or state government insurance programs including Medicaid [1].

Indiana Pharmacy Access: Retail, Mail-Order, and 503A Options

Dayvigo is stocked at most major Indiana retail chains, including CVS, Walgreens, Kroger Pharmacy, and Meijer Pharmacy, as well as independent pharmacies. Because lemborexant is Schedule IV, federal law prohibits dispensing more than a 90-day supply at one time, and electronic or written prescriptions are required; Schedule IV prescriptions cannot be called in verbally in Indiana.

Mail-order pharmacies with Indiana DEA registrations may ship lemborexant to Indiana addresses. Standard ground shipping from most mail-order pharmacies reaches Indiana addresses in two to four business days. Controlled substances shipped via mail must comply with DEA regulations 21 CFR 1301.74, which require tamper-evident packaging and signature confirmation [10].

503A compounding pharmacies licensed in Indiana may prepare extemporaneous formulations of lemborexant for patients with documented medical needs, such as patients who cannot swallow standard tablets. The 503A compounder must hold an active Indiana State Board of Pharmacy license and a DEA Schedule IV registration. Compounded lemborexant is not bioequivalent to the FDA-approved Dayvigo tablet, and patients should be aware of this distinction.

503B outsourcing facilities, by contrast, may not compound lemborexant because it is not on the FDA's list of bulk drug substances eligible for outsourcing facility compounding under Section 503B of the FD&C Act [11]. This means large-scale compounded lemborexant is not legally available from outsourcing facilities.

The HealthRX Indiana Access Framework for lemborexant categorizes the path to first fill into three tiers based on insurance status:

• Tier 1 (commercial insurance with PA): Telehealth visit, PA submission with Z-drug failure documentation, approval within 3 to 10 business days, retail or mail fill.
• Tier 2 (uninsured or underinsured): Telehealth visit, GoodRx or Eisai savings coupon, direct retail fill at approximately $280 to $320 per 30 tablets without discount, or approximately $15 with the Eisai program.
• Tier 3 (Indiana Medicaid): Telehealth or in-person visit, out-of-pocket purchase or appeal to Medicaid with AASM guideline citation and documented Z-drug failure.

Transferring an Existing Dayvigo Prescription to Indiana

A Schedule IV prescription for lemborexant issued by an out-of-state provider may be filled at an Indiana pharmacy if the prescriber holds a valid DEA registration (DEA registrations are federally issued and apply nationwide). The prescription is not required to be written by an Indiana-licensed provider as long as the prescriber is licensed in the state where the patient-provider relationship was established [12].

Pharmacies in Indiana can transfer a Schedule IV prescription from another in-state pharmacy one time only, per DEA regulations 21 CFR 1306.25. Partial fills are permitted for Schedule IV substances. If a patient moves to Indiana and has an existing prescription at an out-of-state pharmacy, the out-of-state pharmacy may transfer it to an Indiana pharmacy once; after that, a new prescription from any DEA-registered provider is required.

Patients relocating to Indiana mid-treatment should contact the original prescribing provider to confirm whether that provider holds an Indiana medical license or telehealth registration, since the patient-provider relationship typically must be maintained within the prescriber's licensed jurisdiction for ongoing controlled-substance prescriptions.

Dosing, Administration, and Safety Considerations

The FDA-approved doses are 5 mg and 10 mg. The starting dose for most adults is 5 mg taken no more than 30 minutes before bedtime with at least 7 hours remaining before the planned waking time [1]. The dose may be increased to 10 mg if 5 mg is well tolerated but insufficiently effective.

Adults aged 65 and older should start at 5 mg and not exceed 5 mg, based on pharmacokinetic data showing higher exposure in older adults [1]. Patients with moderate hepatic impairment should also not exceed 5 mg. Dayvigo is contraindicated in narcolepsy.

The most common adverse effects reported in SUNRISE-1 and SUNRISE-2 were somnolence (10 to 12% at 10 mg vs. 1% placebo), headache (7%), and dizziness (3%) [2, 3]. Next-day driving impairment was measurable at the 10 mg dose in a dedicated driving simulation study; 5 mg did not produce statistically significant impairment versus placebo [1].

Complex sleep behaviors including sleepwalking, sleep driving, and sleep-related eating have been reported with all approved hypnotics including lemborexant. The FDA added a Boxed Warning for complex sleep behaviors to all orexin receptor antagonists and Z-drugs in 2019 [13]. Patients with a prior history of complex sleep behaviors on any hypnotic should generally not receive lemborexant.

Drug interactions worth flagging at the prescribing visit:

• Strong CYP3A inhibitors (clarithromycin, itraconazole, ritonavir): Contraindicated with lemborexant or requiring dose reduction to 5 mg maximum.
• Moderate CYP3A inhibitors (fluconazole, erythromycin): Dose should not exceed 5 mg.
• Strong or moderate CYP3A inducers (rifampin, carbamazepine, St. John's Wort): Avoid concurrent use; lemborexant plasma concentrations drop substantially, reducing efficacy.
• Other CNS depressants (alcohol, benzodiazepines, opioids): Additive sedation; co-prescribing requires careful risk-benefit assessment [1].

How Long Until You Receive Dayvigo After Contacting a Provider?

The timeline from first contact to first dose depends on the pathway chosen.

Telehealth with mail-order pharmacy: Same-day video visit is possible at most platforms. E-prescription transmittal occurs within minutes of the appointment. Standard mail-order shipping to an Indiana address takes two to five business days. Total time: three to seven business days in most cases.

Telehealth with local Indiana retail pharmacy: Same-day visit, same-day e-prescription, same-day fill if the drug is in stock. Most large Indiana retail pharmacies stock lemborexant. Total time: one business day.

Prior authorization pathway: Add three to ten business days for insurer review. Urgent PA requests can sometimes be processed in 24 to 72 hours when the prescriber submits a peer-to-peer review call with the plan's medical director.

Indiana Medicaid appeal pathway: Administrative appeals through Hoosier Health can take 30 to 90 days. Patients needing immediate coverage should use an Eisai savings card while the appeal is pending if commercially co-pays are involved, or pay out of pocket and seek reimbursement after a favorable Medicaid determination.